Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier.

Haqqani AS, Delaney CE, Brunette E, Baumann E, Farrington GK, Sisk W, Eldredge J, Ding W, Tremblay TL, Stanimirovic DB.

J Cereb Blood Flow Metab. 2018 Apr;38(4):727-740. doi: 10.1177/0271678X17740031. Epub 2017 Nov 15.

2.

A comparative study of cognitive behavioural therapy and shared reading for chronic pain.

Billington J, Farrington G, Lampropoulou S, Lingwood J, Jones A, Ledson J, McDonnell K, Duirs N, Humphreys AL.

Med Humanit. 2017 Sep;43(3):155-165. doi: 10.1136/medhum-2016-011047. Epub 2016 Dec 9.

PMID:
27941097
3.

Shared Reading: assessing the intrinsic value of a literature-based health intervention.

Longden E, Davis P, Billington J, Lampropoulou S, Farrington G, Magee F, Walsh E, Corcoran R.

Med Humanit. 2015 Dec;41(2):113-20. doi: 10.1136/medhum-2015-010704. Epub 2015 Jun 12.

PMID:
26070845
4.

Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies.

Stanimirovic D, Kemmerich K, Haqqani AS, Farrington GK.

Adv Pharmacol. 2014;71:301-35. doi: 10.1016/bs.apha.2014.06.005. Epub 2014 Aug 23. Review.

PMID:
25307221
5.

A novel platform for engineering blood-brain barrier-crossing bispecific biologics.

Farrington GK, Caram-Salas N, Haqqani AS, Brunette E, Eldredge J, Pepinsky B, Antognetti G, Baumann E, Ding W, Garber E, Jiang S, Delaney C, Boileau E, Sisk WP, Stanimirovic DB.

FASEB J. 2014 Nov;28(11):4764-78. doi: 10.1096/fj.14-253369. Epub 2014 Jul 28.

PMID:
25070367
6.

In vitro and in vivo methods for assessing FcRn-mediated reverse transcytosis across the blood-brain barrier.

Caram-Salas N, Boileau E, Farrington GK, Garber E, Brunette E, Abulrob A, Stanimirovic D.

Methods Mol Biol. 2011;763:383-401. doi: 10.1007/978-1-61779-191-8_26.

PMID:
21874466
7.

Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis.

Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, Eldredge J, Capili A, Mi S, Graff C, Garber E.

Protein Sci. 2010 May;19(5):954-66. doi: 10.1002/pro.372.

8.

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, Farrington GK, Lugovskoy A, Joseph I, Bailly V, Wang X, Garber E, Browning J, Glaser SM.

MAbs. 2009 Mar-Apr;1(2):128-41. Epub 2009 Mar 11.

9.

Stoichiometry of LTbetaR binding to LIGHT.

Eldredge J, Berkowitz S, Corin AF, Day ES, Hayes D, Meier W, Strauch K, Zafari M, Tadi M, Farrington GK.

Biochemistry. 2006 Aug 22;45(33):10117-28.

PMID:
16906770
10.

Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor).

Cachero TG, Schwartz IM, Qian F, Day ES, Bossen C, Ingold K, Tardivel A, Krushinskie D, Eldredge J, Silvian L, Lugovskoy A, Farrington GK, Strauch K, Schneider P, Whitty A.

Biochemistry. 2006 Feb 21;45(7):2006-13.

PMID:
16475789
11.

Small-molecule inhibition of TNF-alpha.

He MM, Smith AS, Oslob JD, Flanagan WM, Braisted AC, Whitty A, Cancilla MT, Wang J, Lugovskoy AA, Yoburn JC, Fung AD, Farrington G, Eldredge JK, Day ES, Cruz LA, Cachero TG, Miller SK, Friedman JE, Choong IC, Cunningham BC.

Science. 2005 Nov 11;310(5750):1022-5.

12.

Multidomain and multifunctional glycosyl hydrolases from the extreme thermophile Caldicellulosiruptor isolate Tok7B.1.

Gibbs MD, Reeves RA, Farrington GK, Anderson P, Williams DP, Bergquist PL.

Curr Microbiol. 2000 May;40(5):333-40.

PMID:
10706665
13.

Autoantibodies to leukocyte alphaMbeta2 integrin glycoproteins in HIV infection.

Rubinstein DB, Farrington GK, O'Donnell C, Hartman KR, Wright DG.

Clin Immunol. 1999 Mar;90(3):352-9.

PMID:
10075864
14.

Anti-CD11b monoclonal antibody improves myocardial function after six hours of hypothermic storage.

Forbess JM, Hiramatsu T, Nomura F, Miura T, Farrington GK, Sokolowski K, Bree M, Mayer JE Jr.

Ann Thorac Surg. 1995 Nov;60(5):1238-44.

PMID:
8526606
15.

Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation.

Ruhl M, Himmelspach M, Bahr GM, Hammerschmid F, Jaksche H, Wolff B, Aschauer H, Farrington GK, Probst H, Bevec D, et al.

J Cell Biol. 1993 Dec;123(6 Pt 1):1309-20.

16.

Threonine synthase of Escherichia coli: inhibition by classical and slow-binding analogues of homoserine phosphate.

Farrington GK, Kumar A, Shames SL, Ewaskiewicz JI, Ash DE, Wedler FC.

Arch Biochem Biophys. 1993 Nov 15;307(1):165-74.

PMID:
7902068
17.

Perturbation of the carboxy terminus of HIV-1 Rev affects multimerization on the Rev responsive element.

Daly TJ, Rennert P, Lynch P, Barry JK, Dundas M, Rusche JR, Doten RC, Auer M, Farrington GK.

Biochemistry. 1993 Aug 31;32(34):8945-54.

PMID:
8364040
18.
19.

Disorder in beta "-aluminas: Dielectric relaxation and x-ray absorption.

denBoer ML, Pak YS, Adamic KJ, Greenbaum SG, Wintersgill MC, Lomax JF, Fontanella JJ, Dunn B, Farrington GC.

Phys Rev B Condens Matter. 1992 Mar 15;45(12):6369-6375. No abstract available.

PMID:
10000400
20.

Blastocystis hominis complicating ulcerative colitis.

Jeddy TA, Farrington GH.

J R Soc Med. 1991 Oct;84(10):623. No abstract available.

21.
22.

Mutational analysis of the human T-cell leukemia virus type I trans-acting rex gene product.

Hofer L, Weichselbraun I, Quick S, Farrington GK, Böhnlein E, Hauber J.

J Virol. 1991 Jun;65(6):3379-83.

23.

The lentivirus regulatory proteins REV and REX are site specific RNA binding proteins.

Farrington GK, Lynch P, Jensen A, Böhnlein E, Doten R, Maione T, Daly T, Rusche J.

Adv Exp Med Biol. 1991;303:15-22.

PMID:
1666813
24.
25.

Primary amino acid sequence of bovine dopamine beta-hydroxylase.

Robertson JG, Desai PR, Kumar A, Farrington GK, Fitzpatrick PF, Villafranca JJ.

J Biol Chem. 1990 Jan 15;265(2):1029-35.

26.

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.

Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD, et al.

Br J Cancer. 1989 Jul;60(1):126-31.

27.

Benzofurans as mechanism-based inhibitors of dopamine beta-hydroxylase.

Farrington GK, Kumar A, Villafranca JJ.

J Med Chem. 1989 Apr;32(4):735-7. No abstract available.

PMID:
2704022
28.

Small bowel obstruction caused by bezoars from intestinal diverticuli.

Billings PJ, Farrington GH.

Br J Surg. 1987 Dec;74(12):1186. No abstract available.

PMID:
3122871
29.

Design and synthesis of phosphonate inhibitors of glutamine synthetase.

Farrington GK, Kumar A, Wedler FC.

J Med Chem. 1987 Nov;30(11):2062-7.

PMID:
2889829
30.

Chondroitin sulfates used as adjuvants for antibody formation and as mitogens for B cells.

Rosen J, Sherman WT, Farrington GL, Thorbecke GJ.

J Biol Response Mod. 1987 Jun;6(3):355-66.

PMID:
2439657
31.

Design and synthesis of new transition-state analogue inhibitors of aspartate transcarbamylase.

Farrington GK, Kumar A, Wedler FC.

J Med Chem. 1985 Nov;28(11):1668-73.

PMID:
4067992
32.

Nd(3+) beta'' alumina platelet laser.

Jansen M, Alfrey A, Stafsudd OM, Dunn B, Yang DL, Farrington GC.

Opt Lett. 1984 Apr 1;9(4):119-21.

PMID:
19721516
33.
34.

Fast ionic transport in solids.

Farrington GC, Briant JL.

Science. 1979 Jun 29;204(4400):1371-9.

PMID:
17814181
35.

Lithium-Sodium Beta Alumina: First of a Family of Co-ionic Conductors?

Roth WL, Farrington GC.

Science. 1977 Jun 17;196(4296):1332-4.

PMID:
17831751
36.

Blood-borne factors in the pulmonary response to sepsis (acute experimental peritonitis).

Farrington GH, Saravis CA, Cossette GR, Miller DA, Clowes GH Jr.

Surgery. 1970 Jul;68(1):136-45. No abstract available.

PMID:
5423736
37.

Circulating factors in the etiology of pulmonary insufficiency and right heart failure accompanying severe sepsis (peritonitis).

Clowes GH Jr, Farrington GH, Zuschneid W, Cossette GR, Saravis C.

Ann Surg. 1970 May;171(5):663-78. No abstract available.

38.

Histologic observations in crytorchidism: the congenital germinal-cell deficiency of the undescended testis.

Farrington GH.

J Pediatr Surg. 1969 Dec;4(6):606-13. No abstract available.

PMID:
4391881
39.

Abnormalities of the upper urinary tract in cryptorchidism.

Farrington GH, Kerr IH.

Br J Urol. 1969 Feb;41(1):77-9. No abstract available.

PMID:
4388245
40.

Germinal cell deficiency of the undescended testis: a congenital defect.

Farrington GH.

Surg Forum. 1969;20:540-2. No abstract available.

PMID:
4392726
41.

Cryptorchidism in uniovular twins.

Farrington GH.

Br J Urol. 1967 Aug;39(4):456-60. No abstract available.

PMID:
4383261
42.

Cardiac pacing.

Siddons AH, Bluestone R, Davies JG, Farrington GH, Harris AM, Leatham A.

Thoraxchir Vask Chir. 1965 Aug;13(4):271-3. No abstract available.

PMID:
5214905
43.

EFFECT OF AZO-COUPLED ANTIBODY IMMUNIZATION ON SKIN HOMOGRAFT SURVIVAL.

FARRINGTON GH.

Nature. 1964 May 23;202:818-9. No abstract available.

PMID:
14187642
44.

SUBUNGUAL HAEMATOMA--AN EVALUATION OF TREATMENT.

FARRINGTON GH.

Br Med J. 1964 Mar 21;1(5385):742-4. No abstract available.

45.

Osteochondrodystrophy (Brailsford, Morquio).

FARRINGTON GG.

Proc R Soc Med. 1953 Feb;46(2):103. No abstract available.

Supplemental Content

Loading ...
Support Center